Testing HPV and p53 to guide vulvar cancer surgery
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at two tumor test results—HPV and p53—to help doctors decide how much tissue to remove during surgery for vulvar squamous cell carcinoma. It’s meant to reduce the risk of the cancer coming back while avoiding unnecessary removal when margins are only close.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with vulvar squamous cell carcinoma confirmed by a pathology test (biopsy/surgery sample).
- Your cancer stage is FIGO I or II (not stage III or IV).
- This is your first (not returning) vulvar cancer—no prior recurrence.
- After your first surgery, the cancer margins are not “cancer at the edge,” but may be close depending on your HPV test and other findings.
- You are 18 years or older and can sign the study consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study looks at how vulvar squamous cell cancer (SCC) spreads to the sentinel lymph node, and how findings may guide treatment. It focuses on specific early-stage tumor features and requires that cancer is found in the sentinel lymph node.
This study looks at how vulva cancer returns (recurrence) over time. It aims to improve follow-up care for people who have had this type of cancer.
This trial tests different treatments for people with oral cancer or precancerous lesions that have a p53 mutation. It aims to find the best approach for early-stage disease to prevent progression.
This trial is for people with early-stage vulvar cancer that can be surgically removed. It looks at the cancer's HPV and p53 status to decide how much tissue to remove, aiming to reduce side effects while keeping the cancer away.
This Phase 2 trial compares two treatment approaches for some women with vulvar squamous cell cancer: chemoradiation first, or chemotherapy first followed by surgery. The goal is to see which strategy works better or is safer for tumors that are hard to remove without major pelvic surgery.
This trial tests combining two drugs, nivolumab (an immunotherapy) and imiquimod (a cream that boosts the immune system), to treat vulvar squamous cell carcinoma. It aims to shrink tumors before surgery and may be an option for women with large or multifocal tumors.
Hear when a new Vulvar Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.